Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 81

1.

Loss of human ICOSL results in combined immunodeficiency.

Roussel L, Landekic M, Golizeh M, Gavino C, Zhong MC, Chen J, Faubert D, Blanchet-Cohen A, Dansereau L, Parent MA, Marin S, Luo J, Le C, Ford BR, Langelier M, King IL, Divangahi M, Foulkes WD, Veillette A, Vinh DC.

J Exp Med. 2018 Dec 3;215(12):3151-3164. doi: 10.1084/jem.20180668.

PMID:
30498080
2.

Developing combination immunotherapies against cancer that make sense.

Veillette A, Davidson D.

Sci Immunol. 2018 Nov 2;3(29). pii: eaav1872. doi: 10.1126/sciimmunol.aav1872. Review.

PMID:
30389799
3.

It takes a village.

Veillette A, Lu Y.

Nat Immunol. 2018 Oct;19(10):1046-1047. doi: 10.1038/s41590-018-0213-0. No abstract available.

PMID:
30224818
4.

Combined mTOR and MEK inhibition is an effective therapy in a novel mouse model for angiosarcoma.

Chadwick ML, Lane A, Thomas D, Smith AR, White AR, Davidson D, Feng Y, Boscolo E, Zheng Y, Adams DM, Gupta A, Veillette A, Chow LML.

Oncotarget. 2018 May 15;9(37):24750-24765. doi: 10.18632/oncotarget.25345. eCollection 2018 May 15.

5.

SIRPα-CD47 Immune Checkpoint Blockade in Anticancer Therapy.

Veillette A, Chen J.

Trends Immunol. 2018 Mar;39(3):173-184. doi: 10.1016/j.it.2017.12.005. Epub 2018 Jan 11. Review.

PMID:
29336991
6.

Two novel mutations in ZAP70 gene that result in human immunodeficiency.

Llamas-Guillén BA, Pastor N, López-Herrera G, González-Serrano ME, Valenzuela-Vázquez L, Bravo-Adame ME, Villanueva-Cabello TM, Gaytán P, Yañez J, Martinez-Duncker I, Ruiz-Fernández M, Veillette A, Espinosa-Padilla SE, Cruz-Munoz ME.

Clin Immunol. 2017 Oct;183:278-284. doi: 10.1016/j.clim.2017.09.005. Epub 2017 Sep 11. No abstract available.

PMID:
28912049
7.

SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin.

Chen J, Zhong MC, Guo H, Davidson D, Mishel S, Lu Y, Rhee I, Pérez-Quintero LA, Zhang S, Cruz-Munoz ME, Wu N, Vinh DC, Sinha M, Calderon V, Lowell CA, Danska JS, Veillette A.

Nature. 2017 Apr 27;544(7651):493-497. doi: 10.1038/nature22076. Epub 2017 Apr 19.

8.

Morpholino-based correction of hypomorphic ZAP70 mutation in an adult with combined immunodeficiency.

Gavino C, Landekic M, Zeng J, Wu N, Jung S, Zhong MC, Cohen-Blanchet A, Langelier M, Neyret O, Lejtenyi D, Rochefort C, Cotton-Montpetit J, McCusker C, Mazer B, Veillette A, Vinh DC.

J Allergy Clin Immunol. 2017 May;139(5):1688-1692.e10. doi: 10.1016/j.jaci.2017.02.002. Epub 2017 Feb 17. No abstract available.

PMID:
28216435
9.

The Csk-Associated Adaptor PAG Inhibits Effector T Cell Activation in Cooperation with Phosphatase PTPN22 and Dok Adaptors.

Davidson D, Zhong MC, Pandolfi PP, Bolland S, Xavier RJ, Seed B, Li X, Gu H, Veillette A.

Cell Rep. 2016 Dec 6;17(10):2776-2788. doi: 10.1016/j.celrep.2016.11.035.

10.

Correction: Deletion of Slam locus in mice reveals inhibitory role of SLAM family in NK cell responses regulated by cytokines and LFA-1.

Guo H, Cranert SA, Lu Y, Zhong MC, Zhang S, Chen J, Li R, Mahl SE, Wu N, Davidson D, Waggoner SN, Veillette A.

J Exp Med. 2016 Sep 19;213(10):2227. doi: 10.1084/jem.2016055209072016c. Epub 2016 Sep 12. No abstract available.

11.

Deletion of Slam locus in mice reveals inhibitory role of SLAM family in NK cell responses regulated by cytokines and LFA-1.

Guo H, Cranert SA, Lu Y, Zhong MC, Zhang S, Chen J, Li R, Mahl SE, Wu N, Davidson D, Waggoner SN, Veillette A.

J Exp Med. 2016 Sep 19;213(10):2187-207. doi: 10.1084/jem.20160552. Epub 2016 Aug 29. Erratum in: J Exp Med. 2016 Sep 19;213(10):2227.

12.

SLAM-associated protein favors the development of iNKT2 over iNKT17 cells.

Michel ML, Lenoir C, Massot B, Diem S, Pasquier B, Sawa S, Rignault-Bricard R, Lehuen A, Eberl G, Veillette A, Leite-de-Moraes M, Latour S.

Eur J Immunol. 2016 Sep;46(9):2162-74. doi: 10.1002/eji.201646313. Epub 2016 Jul 22.

13.

Activation by SLAM Family Receptors Contributes to NK Cell Mediated "Missing-Self" Recognition.

Alari-Pahissa E, Grandclément C, Jeevan-Raj B, Leclercq G, Veillette A, Held W.

PLoS One. 2016 Apr 7;11(4):e0153236. doi: 10.1371/journal.pone.0153236. eCollection 2016.

14.

A hematopoietic cell-driven mechanism involving SLAMF6 receptor, SAP adaptors and SHP-1 phosphatase regulates NK cell education.

Wu N, Zhong MC, Roncagalli R, Pérez-Quintero LA, Guo H, Zhang Z, Lenoir C, Dong Z, Latour S, Veillette A.

Nat Immunol. 2016 Apr;17(4):387-96. doi: 10.1038/ni.3369. Epub 2016 Feb 15.

PMID:
26878112
15.

SLAM family receptors in normal immunity and immune pathologies.

Wu N, Veillette A.

Curr Opin Immunol. 2016 Feb;38:45-51. doi: 10.1016/j.coi.2015.11.003. Epub 2015 Dec 2. Review.

PMID:
26682762
16.

DNAM-1 controls NK cell activation via an ITT-like motif.

Zhang Z, Wu N, Lu Y, Davidson D, Colonna M, Veillette A.

J Exp Med. 2015 Nov 16;212(12):2165-82. doi: 10.1084/jem.20150792. Epub 2015 Nov 9.

17.

Loss of PTPN12 Stimulates Progression of ErbB2-Dependent Breast Cancer by Enhancing Cell Survival, Migration, and Epithelial-to-Mesenchymal Transition.

Li J, Davidson D, Martins Souza C, Zhong MC, Wu N, Park M, Muller WJ, Veillette A.

Mol Cell Biol. 2015 Dec;35(23):4069-82. doi: 10.1128/MCB.00741-15. Epub 2015 Sep 21.

18.

Mosaic partial deletion of PTPN12 in a child with interrupted aortic arch type A.

Duffy EA, Pretorius PR, Lerach S, Lohr JL, Hirsch B, Souza CM, Veillette A, Schimmenti LA.

Am J Med Genet A. 2015 Nov;167A(11):2674-83. doi: 10.1002/ajmg.a.37279. Epub 2015 Aug 6.

PMID:
26250342
19.

A functional polymorphism of Ptpn22 is associated with type 1 diabetes in the BioBreeding rat.

Sarmiento J, Wallis RH, Ning T, Marandi L, Chao G, Veillette A, Lernmark Å, Paterson AD, Poussier P.

J Immunol. 2015 Jan 15;194(2):615-29. doi: 10.4049/jimmunol.1302689. Epub 2014 Dec 12.

20.

Immune cell inhibition by SLAMF7 is mediated by a mechanism requiring src kinases, CD45, and SHIP-1 that is defective in multiple myeloma cells.

Guo H, Cruz-Munoz ME, Wu N, Robbins M, Veillette A.

Mol Cell Biol. 2015 Jan;35(1):41-51. doi: 10.1128/MCB.01107-14. Epub 2014 Oct 13.

Supplemental Content

Loading ...
Support Center